KRSNAANSEQ4 FY2025-26May 25, 2026

Krsnaa Diagnostics Limited

2,960words
3turns
0analyst exchanges
0executives
Key numbers — 40 extracted
68 Million
FY25-26 147 Pathology Labs 18 States/UT Presence in India 331 Districts Presence PAN India 68 Million+ Patients Served In Last 5 Years Krsnaa Diagnostics is one of the fastest growing and Integrate
29%
wth Particulars Q4 FY26 Q4 FY25 Growth Revenue 1,926 1,861 EBIDTA 559 545 EBIDTA Margin 29% 29% 4% 3% - PAT 417 207 102% PAT Margin 22% 11% 1,051 bps EPS 12.8 6.3 103% No. of
4%
culars Q4 FY26 Q4 FY25 Growth Revenue 1,926 1,861 EBIDTA 559 545 EBIDTA Margin 29% 29% 4% 3% - PAT 417 207 102% PAT Margin 22% 11% 1,051 bps EPS 12.8 6.3 103% No. of Patient
3%
rs Q4 FY26 Q4 FY25 Growth Revenue 1,926 1,861 EBIDTA 559 545 EBIDTA Margin 29% 29% 4% 3% - PAT 417 207 102% PAT Margin 22% 11% 1,051 bps EPS 12.8 6.3 103% No. of Patient Ser
102%
Growth Revenue 1,926 1,861 EBIDTA 559 545 EBIDTA Margin 29% 29% 4% 3% - PAT 417 207 102% PAT Margin 22% 11% 1,051 bps EPS 12.8 6.3 103% No. of Patient Served NABL Accreditatio
22%
,926 1,861 EBIDTA 559 545 EBIDTA Margin 29% 29% 4% 3% - PAT 417 207 102% PAT Margin 22% 11% 1,051 bps EPS 12.8 6.3 103% No. of Patient Served NABL Accreditation (Pathology lab
11%
1,861 EBIDTA 559 545 EBIDTA Margin 29% 29% 4% 3% - PAT 417 207 102% PAT Margin 22% 11% 1,051 bps EPS 12.8 6.3 103% No. of Patient Served NABL Accreditation (Pathology lab) NA
1,051 bps
1 EBIDTA 559 545 EBIDTA Margin 29% 29% 4% 3% - PAT 417 207 102% PAT Margin 22% 11% 1,051 bps EPS 12.8 6.3 103% No. of Patient Served NABL Accreditation (Pathology lab) NABH Accredit
103%
Margin 29% 29% 4% 3% - PAT 417 207 102% PAT Margin 22% 11% 1,051 bps EPS 12.8 6.3 103% No. of Patient Served NABL Accreditation (Pathology lab) NABH Accreditation (Radiology Cent
1%
t Served NABL Accreditation (Pathology lab) NABH Accreditation (Radiology Centre) 4.8 4.7 1% 54 54 51 32 6% 74% Note: 1. Financial results of the Company are best monitored on an annual
6%
creditation (Pathology lab) NABH Accreditation (Radiology Centre) 4.8 4.7 1% 54 54 51 32 6% 74% Note: 1. Financial results of the Company are best monitored on an annual basis, as there is
74%
itation (Pathology lab) NABH Accreditation (Radiology Centre) 4.8 4.7 1% 54 54 51 32 6% 74% Note: 1. Financial results of the Company are best monitored on an annual basis, as there is a cer
Guidance — 2 items
Note
opening
Copyright 2026 18 Retail Summary Retail Revenue ( INR Mn) Patient Count (Mn) Test Volume (Mn) 158 0.15 0.47 64 0.18 0.09 Q4 FY25 Q4 FY26 Q4 FY25 Q4 FY26 Q4 FY25 Q4 FY26 Revenue Per Patient (INR) 1,503 711 Q4 FY25 Q4 FY26 Retail Revenue Contribution to Group Revenue Q4 FY25 3% Q4 FY26 8% RPL Krsnaa RPL Krsnaa 97% 92% © Krsnaa Diagnostics Ltd.
Note
opening
Customized integrated health screening packages targeting early disease detection — at an affordable price point in Tier-2 ,3, and 4 geographies to cater larger audience base E N G I N E 4 200+ CT/MRI Centres (Target) E N G I N E 5 Radiology Retail Penetration Home Collection Scale-Up 20+ E N G I N E 6 Cities with Home Collection Network Leveraging All Business Channels Low CAC via Digital Channels Leveraging the existing CT/MRI network (149 CT + 41 MRI centres, Q4 FY26) for retail volume.
Speaking time
Business outlook
1
Cost Optimisation
1
Note
1
Opening remarks
Business outlook
• Radiology avg tenure term ~10+ years Government OPD & IPD patients attributed to: • District Hospitals
Cost Optimisation
• Volume-driven economies of • Subdistrict Hospitals scale • Pathology avg tenure term ~5+ • Community Healthcare centres • Building Efficiency years • Primary Healthcare Centres, etc. Skilled Human Resource Robust IT Infrastructure Operational Excellence • 350+ qualified doctors • 3,000+ skilled technicians • 1,000+ professionals Advanced Fully Integrated IT system: • In-house PACS & LIMS • Synchronizing AI • Multiple and multi-level automation • Pathology: Common processing units for PPP and retail both • Radiology: Common imaging centres for PPP and retail both © Krsnaa Diagnostics Ltd. All Rights Reserved. Copyright 2026 11 Our Pricing - “Everyone Can Afford” Segment Test Competition 1 Competition 2 Competition 3 Krsnaa % lower from competitors Radiology Radiology Pathology Pathology Pathology Pathology Pathology Pathology CT Brain MRI Brain CBC Blood Sugar Thyroid Vitamin D Vitamin B12 HbA1C 4,500 8,000 250 85 500 1,500 1,000 550 4,500 8,250 250 80 550 1,250 1,100 440 3,500 7,000
Note
Amounts are in INR. Above mentioned examples from our comprehensive test lists for illustration purpose only and referenced from publicly available information © Krsnaa Diagnostics Ltd. All Rights Reserved. Copyright 2026 12 Patient Experience at Its Best Growth Engine- Rajasthan Pathology Kishangarh, Mother Lab Alwar, Mother Lab © Krsnaa Diagnostics Ltd. All Rights Reserved. Copyright 2026 Actual centre images 14 Growth Engine- Rajasthan Pathology Rawatsar, Hub Lab Sawai Madhopur, Mother Lab © Krsnaa Diagnostics Ltd. All Rights Reserved. Copyright 2026 Actual centre images 15 Growth Engine- Rajasthan Pathology © Krsnaa Diagnostics Ltd. All Rights Reserved. Copyright 2026 Actual centre images 16 ESG Initiatives ESG Initiatives Solar system capable of generating 80 KW of green energy ~1,77,000+ hours Learning and development programs for employees Using Biodegradable bags for BMW Workflow digitization eliminated the monthly need for 10,000+ paper Effluent treatment plants for wastewater
← All transcriptsKRSNAA stock page →